← Oncology Approval Tracker

FDA DECISION ·

Hernexeos

zongertinib · Boehringer Ingelheim Pharmaceuticals

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with unresectable or metastatic nonsquamous NSCLC and a HER2 (ERBB2) activating tyrosine kinase domain mutation by an FDA-approved test after prior systemic therapy.

LAMPGEN ANALYSIS

Why it matters

An oral HER2 kinase inhibitor became available for this molecular subgroup after systemic therapy.

What research teams should watch

Require the molecular report to identify the activating kinase-domain variant, since HER2 amplification or staining alone does not establish eligibility.

PRIMARY RECORDS

Sources